Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.7152W HIGH $7.75
Volume
35.25 K
Value Traded
841.49 K
Short % Float
5.94%
+3.21%Week
+7.69%1 Month
-5.62%3 Month
+19.05%6 Month
+1.26%5 Year
+1.26%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
116.46 M
EPS (TTM)
-0.92
P/E Ratio
-
Ent. Value
73.28 M
Total Shares
23.47 M
Float Shares
20.01 M
Insiders
14.69%
Institutions
33.21%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
COYA Catalyst Timeline
Dated clinical, regulatory and corporate events for Coya Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Coya Therapeutics, Inc.
225Total events
11Upcoming
42Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompleteTrial
Full enrollment completed in Phase 2/3 ALSTARS trial of COYA 302 in ALS
amyotrophic lateral sclerosis (ALS)source ↗
▲Enrollment MilestoneTrial
100th participant enrolled in Phase 2/3 ALSTARS trial of COYA 302 in ALS
amyotrophic lateral sclerosis (ALS)source ↗
▲Preclinical PoCPreclinical
Preclinical results for COYA 303 published in International Journal of Molecular Sciences
Peripheral and CNS Inflammationsource ↗
▲Fast Track DesignationDesignation
Received FDA Fast Track Designation for COYA 302 for ALS
ALSsource ↗
▲Enrollment MilestoneTrial
First cohort progressed into 24-week blinded active treatment extension phase
ALSsource ↗
▲PublicationPresentation
Publication in Annals of Clinical and Translational Neurology demonstrating correlation between biomarker data and clinical outcomes
ALSsource ↗
●Oral PresentationPresentation
Scientific presentations on ALSTARS trial design at ALS Drug Development Summit and ENCALS Meeting 2026
ALSsource ↗
◆Oral PresentationPresentation
Virtual webinar on intersection of repetitive head trauma, brain inflammation and neurodegenerative disease
repetitive head trauma, brain inflammation, neurodegenerative diseasesource ↗
▲OLE InitiatedTrial
First cohort of patients in ALSTARS trial began blinded active-treatment extension phase
ALSsource ↗
◆Oral PresentationPresentation
Presentation of ALSTARS trial design at 5th ALS Drug Development Summit
ALSsource ↗
▲Fast Track DesignationDesignation
FDA Fast Track Designation for COYA 302 in ALS
Amyotrophic Lateral Sclerosis (ALS)source ↗
▲PublicationPresentation
Publication of biomarker study in Annals of Clinical and Translational Neurology
ALSsource ↗
◆Enrollment CompleteTrial
Full enrollment target for ALSTARS
Amyotrophic Lateral Sclerosis (ALS)source ↗
◆Oral PresentationPresentation
Webinar on ALS drug development, patient landscape, and ongoing clinical trial
Amyotrophic Lateral Sclerosis (ALS)source ↗
▼Equity OfferingCorporate
Private placement of 2,522,727 shares at $4.40 per share for gross proceeds of $11.1 million
◆PublicationPresentation
Longitudinal assessment of biomarkers in ALS publication expected
ALSsource ↗
▲IND ClearanceIND
Health Canada accepts CTA for COYA 302 ALSTARS trial
amyotrophic lateral sclerosis (ALS)source ↗
▲Trial InitiationTrial
ALSTARS trial underway in the United States
amyotrophic lateral sclerosis (ALS)source ↗
▲IND ClearanceIND
FDA acceptance of IND for COYA 302 in ALS
Amyotrophic Lateral Sclerosis (ALS)source ↗
▲Milestone PaymentCorporate
Expect to receive $4.2 million milestone payment from Dr. Reddy's upon first patient dosing
Amyotrophic Lateral Sclerosis (ALS)source ↗
▲Trial InitiationTrial
Launched ALSTARS Phase 2 trial of COYA 302 in ALS
Amyotrophic Lateral Sclerosis (ALS)source ↗
▲Enrollment CompleteTrial
Completed patient enrollment in investigator-initiated FTD study
Frontotemporal Dementia (FTD)source ↗
▲Preclinical PoCPreclinical
Reported results from first cohort of preclinical in-vivo animal study of COYA 303
Neurodegenerative disorderssource ↗
▲First Patient DosedTrial
First patient dosed in COYA 302 ALSTARS Trial
Amyotrophic Lateral Sclerosis (ALS)source ↗
◆Full ResultsClinical Data
Presentation and publication of comprehensive in-vivo animal data set of COYA 303
Neurodegenerative disorderssource ↗
◆Biomarker DataClinical Data
Publication of longitudinal data on NfL and oxidative stress markers in ALS patients
Amyotrophic Lateral Sclerosis (ALS)source ↗
◆Additional DataClinical Data
Report additional single cell proteomics data from completed Phase 2 AD study
Alzheimer's disease (AD)source ↗
◆Topline ReadoutClinical Data
Top-line clinical data release for investigator-initiated FTD trial
Frontotemporal Dementia (FTD)source ↗
●IND SubmissionIND
IND submission for COYA 302 in FTD anticipated in Q4 2025
Frontotemporal Dementia (FTD)source ↗
●PublicationPresentation
Published results linking inflammation and oxidative stress to PD progression in Frontiers of Immunology
Parkinson's Diseasesource ↗
▲Patent GrantedIP / Competition
U.S. patent granted for stable ready-to-use liquid IL-2 formulation
●IND SubmissionIND
Submitted additional nonclinical data to FDA to support start of COYA 302 Phase 2 trial in ALS
ALSsource ↗
▲Topline ReadoutClinical Data
Positive interim results of investigator-initiated study with LD IL-2 and CTLA4-Ig in FTD
Frontotemporal Dementiasource ↗
●Full ResultsClinical Data
Publication of COYA 303 in vitro study in NeuroImmune Pharmacology and Therapeutics
Inflammatory diseasessource ↗
▲Patent GrantedIP / Competition
Filing of new intellectual property portfolio for COYA 303 and COYA 301 in combination with GLP-1 Receptor Agonist
●IND SubmissionIND
FDA IND submission for COYA 302 in ALS expected in Q2 2025
Amyotrophic Lateral Sclerosissource ↗
●IND SubmissionCOYA-302IND
Submission of additional nonclinical data to support start of COYA-302 Phase 2 trial in ALS
Amyotrophic Lateral Sclerosissource ↗
Past FDA Catalysts and PDUFA Decisions
How COYA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | LD IL-2 + CTLA4-Ig | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D31 / 100
Pipeline Score
$3M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 65%
Micro Cap(rank 428 of 658)
Percentile Rank
Coya Therapeutics, Inc. faces pipeline headwinds (31/100), with $39M risk-adjusted pipeline value, led by COYA 302 in Amyotrophic Lateral Sclerosis (ALS) (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| COYA 302 Small moleculeNCT07161999 | Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | RECRUITING | 120 | Jul 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every COYA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| COYA 302 Fast Track | ALS | 2026-04-10 | p< 0.001 for 4-HNE and LBP; p= 0.001 for NfL; p< 0.001 for the rate of disease progression as measured by ALSFRS-R; ALSFRS-R scores at week 24 (33.75 ±3.3) and week 48 (32 ±7.8) after initiation of treatment with LD IL-2 and CTLA-4 Ig were not statistically different compared to the ALSFRS-R score at baseline (33.5 ±5.9)Read More | Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALSRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pavao Mark HDirector | Grant/Award | 10,000 10,000 held | $0.00 | 04/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in COYA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 0.2 % (-33.3 %) | 994.00 K | 170.00 K | -59.56% ( -250.36 K) |
COYA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How COYA ranks across every disease it competes in
Competitive Position is a premium feature
See how COYA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCOYA News
COYACoya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics has announced the completion of full enrollment in its Phase 2/3 ALSTARS Trial, which involves 120 participants. The trial is evaluating COYA 302, a combination of low-dose IL-2 and CTLA-4 Ig, aimed at treating amyotrophic lateral sclerosis (ALS). This development marks a significant step in the company's research efforts in neurodegenerative disorders.
Read more →COYACoya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Coya Therapeutics has announced the enrollment of its 100th participant in the Phase 2/3 ALSTARS Trial for COYA 302, a treatment for amyotrophic lateral sclerosis (ALS). This trial evaluates the efficacy of a combination of low-dose IL-2 and CTLA-4 Ig. The milestone reflects progress in developing therapies for neurodegenerative disorders.
Read more →COYACoya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
Coya Therapeutics has announced the publication of preclinical results for COYA 303, demonstrating its immunomodulatory effects in a model of peripheral and CNS inflammation. The findings were published in the International Journal of Molecular Sciences, contributing to the understanding of glucagon-like peptide-1 receptor agonists. This research may enhance therapeutic applications in related diseases.
Read more →COYACoya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics, a clinical-stage biotech firm, reported its financial results for Q2 2026, highlighting significant advancements in its lead program, COYA 302. CEO Arun Swaminathan emphasized the progress made during this period. The corporate update suggests a positive outlook for the company's future developments.
Read more →COYACoya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Coya Therapeutics is set to present the design of its ALSTARS trial at the upcoming ENCALS 2026 Meeting. This presentation aims to share insights into the trial's structure and objectives, contributing to the ongoing discussions in the field of ALS research.
Read more →COYACoya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
Coya Therapeutics is set to host a virtual webinar focusing on the relationship between repetitive head trauma, brain inflammation, and neurodegenerative diseases. This event aims to provide insights into how these factors interconnect and their implications for treatment. Further details about the webinar were not provided in the article.
Read more →COYACoya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
Coya Therapeutics has announced that the first cohort of patients in the ALSTARS trial has commenced the blinded active-treatment extension phase. This marks a significant step in the trial process, although specific details about patient outcomes or trial objectives were not disclosed. The announcement indicates progress in the clinical trial's timeline.
Read more →COYACoya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
Coya Therapeutics is set to present the design of its ALSTARS trial at the upcoming 5th ALS Drug Development Summit. This presentation is expected to highlight the company's innovative approach to ALS treatment. Further details on the trial's objectives and methodologies will be discussed during the event.
Read more →COYACoya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics has released its financial results for the first quarter of 2026 along with a corporate update. The article does not provide specific details regarding the financial performance or any significant developments within the company. Further insights into their strategies and future plans were also not disclosed.
Read more →COYACoya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics has been granted Fast Track Designation by the U.S. FDA for its investigational treatment COYA 302, aimed at addressing Amyotrophic Lateral Sclerosis (ALS). This designation is intended to facilitate the development and review process for drugs that treat serious conditions and fill unmet medical needs. The move is expected to accelerate the availability of COYA 302 to patients.
Read more →COYA▼ -7.9%on this news
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Coya Therapeutics has published a study demonstrating a correlation between serum biomarkers and clinical outcomes in ALS patients. The research, involving 100 ALS patients and 100 healthy controls, found that specific biomarkers were significantly linked to survival and disease progression. These findings support the ongoing ALSTARS trial of COYA 302, which aims to enhance Treg function in ALS treatment.
Read more →COYACoya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Coya Therapeutics has announced a planned transition in its board of directors, appointing Mark H. Pavao as an independent director. This change is part of the company's strategy to enhance its governance and oversight. Further details regarding the transition were not provided in the announcement.
Read more →COYACoya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
Coya Therapeutics has provided a corporate update and reported its financial results for FY 2025, highlighting significant advancements in its clinical trials, particularly the launch of the ALSTARS Phase 2 trial for ALS. The company received FDA acceptance for its IND application for COYA 302 targeting frontotemporal dementia and reported promising interim findings for COYA 303. Financially, Coya secured $23 million in a public offering, extending its cash runway into the second half of 2027, despite an increased net loss.
Read more →COYACoya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Coya Therapeutics will host a webinar on February 17, 2026, focusing on ALS drug development and patient care. The event will cover recent advancements and ongoing challenges in ALS treatment, highlighting Coya's COYA 302 therapy and its ALSTARS Phase 2 clinical trial. The webinar aims to engage participants in discussions about the evolving landscape of ALS therapies.
Read more →COYACoya Therapeutics Announces $11.1 Million Private Placement
Coya Therapeutics announced a private placement of 2,522,727 shares at $4.40 each, raising approximately $11.1 million. The funds will be used to enhance manufacturing activities for COYA 302, an investigational therapy for neurodegenerative diseases. The offering is expected to close by January 30, 2026, pending customary conditions.
Read more →COYACoya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Coya Therapeutics' CEO Dr. Arun Swaminathan issued a letter to stockholders highlighting the company's strong position in advancing therapies for neurodegenerative diseases like ALS and FTD. With recent IND approvals and promising early clinical results, Coya is focused on key milestones in 2026. The company maintains a solid financial footing with significant cash reserves, allowing for continued operational momentum.
Read more →COYA▼ -5.1%on this news
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
Coya Therapeutics announced that the FDA has accepted its IND application for COYA 302, aimed at treating frontotemporal dementia (FTD). This condition currently has no approved treatments, highlighting a significant unmet medical need. The investigational therapy is designed to enhance regulatory T cell function and may provide a new approach to managing FTD. Clinical trials are expected to follow, with topline results from an ongoing study anticipated soon.
Read more →COYACoya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics has received acceptance from Health Canada for its Clinical Trial Application (CTA) for COYA 302, allowing the initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers. This Phase 2, placebo-controlled study aims to evaluate the efficacy and safety of COYA 302 in treating amyotrophic lateral sclerosis (ALS). The trial is already underway in the United States and will now expand to Canada, enhancing recruitment efforts.
Read more →About Coya Therapeutics, Inc.
Headquarters12645 MEMORIAL DR., SUITE F1 #305, HOUSTON, TX, 77024
BIOPHARMAWATCH ELITE PLUS
Trade the next COYA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime